eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Randomized phase II study of docetaxel followed by vandetanib (ZD6474) vs. docetaxel plus vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Intervention
  4. Resource Description
    RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether docetaxel is more effective when given alone or together with vandetanib. PURPOSE: This randomized phase II trial is studying docetaxel given together with or without vandetanib to see how well it works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
  5. Contact
    Berenberg, Jeffrey
  6. PI
    Berenberg, Jeffrey
  7. Topic
    ovarian cancer
  8. Study Population
    Females age 18 and older with histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal carcinoma.
  9. Funded by
  10. Phase
    Phase 2 clinical trial
  11. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016